Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
129.93
+1.80 (1.40%)
At close: Mar 9, 2026, 4:00 PM EDT
130.02
+0.09 (0.07%)
After-hours: Mar 9, 2026, 5:56 PM EDT
Neurocrine Biosciences Revenue
In the year 2025, Neurocrine Biosciences had annual revenue of $2.86B with 21.45% growth. Neurocrine Biosciences had revenue of $805.50M in the quarter ending December 31, 2025, with 28.33% growth.
Revenue (ttm)
$2.86B
Revenue Growth
+21.45%
P/S Ratio
4.54
Revenue / Employee
$1,430,250
Employees
2,000
Market Cap
13.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.86B | 505.20M | 21.45% |
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Haleon | 14.85B |
| Viatris | 14.30B |
| Elanco Animal Health | 4.72B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.18B |
| Amneal Pharmaceuticals | 3.02B |
| Hims & Hers Health | 2.35B |
NBIX News
- 7 hours ago - Neurocrine Biosciences, Inc. (NBIX) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 3 days ago - BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) - PRNewsWire
- 6 days ago - Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 13 days ago - Neurocrine Biosciences to Present at Upcoming Investor Conferences in March - PRNewsWire
- 24 days ago - Neurocrine Biosciences: Growth Beyond Just Ingrezza - Seeking Alpha
- 25 days ago - Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance - Benzinga
- 25 days ago - Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting - Seeking Alpha
- 25 days ago - Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript - Seeking Alpha